Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0002095702-25-000002
Filing Date
2025-11-10
Accepted
2025-11-10 21:07:59
Documents
2
Period of Report
2025-10-31

Document Format Files

Seq Description Document Type Size
1 form3-11112025_021155.html 3  
1 form3-11112025_021155.xml 3 7089
2 ex24-11112025_021157.htm EX-24 6034
  Complete submission text file 0002095702-25-000002.txt   14567
Mailing Address 201 HASKINS WAY SOUTH SAN FRANCISCO CA 94080
Business Address 201 HASKINS WAY SOUTH SAN FRANCISCO CA 94080 650 695-0677
Lyell Immunopharma, Inc. (Issuer) CIK: 0001806952 (see all company filings)

EIN.: 833006753 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O LYELL IMMUNOPHARMA, INC. 201 HASKINS WAY, SUITE 101 SOUTH SAN FRANCISCO CA 94080
Business Address
Bulis Veronica Sanchez (Reporting) CIK: 0002095702 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-40502 | Film No.: 251468035